FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
IPO Year: 2014
Exchange: NASDAQ
Website: fibrogen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $4.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 6/26/2023 | Buy → Hold | Stifel | |
| 6/26/2023 | Buy → Neutral | BofA Securities | |
| 6/26/2023 | Outperform → Mkt Perform | Raymond James | |
| 6/26/2023 | Outperform → Mkt Perform | William Blair | |
| 6/2/2023 | $23.00 → $32.00 | Hold → Buy | Stifel |
| 1/31/2023 | Mkt Perform → Outperform | William Blair | |
| 1/26/2023 | $35.00 | Mkt Perform → Outperform | Raymond James |
| 1/5/2023 | $18.00 → $27.00 | Neutral → Buy | BofA Securities |
| 3/1/2022 | $10.00 → $9.00 | Sell | Goldman Sachs |
Fastest customizable press release news feed in the world
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGenFibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadusta
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f
FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burdenCompany intends to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced positive feedback from its Type C meeting with the FDA, supporting the advancement of roxadustat for the treatment of anemia in patients with LR-MDS and high RBC transfusion burden, based on a post-hoc subgroup analysis from the MATTERHORN Phase 3 trial. "We
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call b
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen's common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company's existing trading symbol "FGEN," with the new CUSIP number 31572Q881. The Reverse Stock Split was previously approved by stockholders at the Company's annual meeting of stockholders held on June 4, 2025 ("2025 Annual Meeting"), with the final ratio determined by the Company's Board of Directors. O
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by pho
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen's management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) pat
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN FRANCISCO, March 28, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the peer-reviewed publication titled "A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration Resistant Prostate Cancer" in the Journal of Clinical Oncology. The manuscript includes the complete results from the Fortis Therapeutics-sponsored Phase 1 study of FO
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
8-K - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
10-Q - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
SCHEDULE 13G/A - FIBROGEN INC (0000921299) (Subject)
8-K - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
10-Q - FIBROGEN INC (0000921299) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
3 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously
Stifel downgraded FibroGen from Buy to Hold
BofA Securities downgraded FibroGen from Buy to Neutral
Raymond James downgraded FibroGen from Outperform to Mkt Perform
William Blair downgraded FibroGen from Outperform to Mkt Perform
Stifel upgraded FibroGen from Hold to Buy and set a new price target of $32.00 from $23.00 previously
William Blair upgraded FibroGen from Mkt Perform to Outperform
Raymond James upgraded FibroGen from Mkt Perform to Outperform and set a new price target of $35.00
BofA Securities upgraded FibroGen from Neutral to Buy and set a new price target of $27.00 from $18.00 previously
Goldman Sachs reiterated coverage of FibroGen with a rating of Sell and set a new price target of $9.00 from $10.00 previously
This live feed shows all institutional transactions in real time.
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G - FIBROGEN INC (0000921299) (Subject)
Live finance-specific insights
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call b
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by pho
Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025 FibroGen to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 17, 2025
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To acc
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure Company's cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024FibroGen to host conference call and webcast presentation today at
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full year net product revenue guidance of $135 million to $150 million, representing full year total roxadustat net sales in China1 between $330 million to $350 m
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: Click here To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the "Events and Pres
Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus R&D investment on FG-3246 and PET46, a first-in-class anti-CD46 antibody-drug conjugate and companion PET imaging agent for metastatic castration-resistant prostate cancer (mCRPC) Presented compelling preliminary data from dose escalation portion of Phase 1b/2 investigator-sponsored study of FG-3246, in combination with enzalutamide, in patients with mCRPC at the 2024 American Society of Clinical Oncology Annual Meeting Topline results from Phase 2 portion of the study expected in 1H
Live Leadership Updates
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the appointment of Thane Wettig as the Company's interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen's Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period. "Than
Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t
Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company. "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this manageme
SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September 6, 2021, and will remain with FibroGen through March 31, 2022 serving as Executive Advisor to the CEO to ensure a smooth transition. "On behalf of the board, shareholders, and our employees, I want to thank Pat for his contributions as Chief Financial Officer and dedicated service over the past 21 years," said Enrique Conterno, Chief Executive Officer, FibroGen. "With his leadership, FibroGen transitioned from a private to public compan
SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience. "Great science and innovation are the backbone of FibroGen and what enable us to develop transformational medicines for patients. With John's leadership, we will continue our legacy of biological breakthroughs and advancing first-in-class therapeutics," said Enrique Conterno, Chief Executive Officer, FibroGen. "John's expertise and experience make him the ideal person to lead FibroGen's sc